Cargando…

A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours

BACKGROUND: To examine the angiopoietin pathway inhibitor trebananib IV plus the anti-VEGF agents bevacizumab or motesanib in advanced solid tumours. METHODS: In this open-label phase 1b study, patients received IV trebananib 3 mg kg(−1) QW plus bevacizumab 15 mg kg(−1) Q3W (cohort 1) or motesanib o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, David S., Kurzrock, Razelle, Mulay, Marilyn, Rasmussen, Erik, Wu, Benjamin M., Bass, Michael B., Zhong, Zhandong D., Friberg, Greg, Rosen, Lee S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294348/ https://www.ncbi.nlm.nih.gov/pubmed/25525888

Ejemplares similares

Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours
por: Price, T J, et al.
Publicado: (2008)

Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
por: Abou‐Alfa, Ghassan K., et al.
Publicado: (2017)

Challenges in Developing a Validated Biomarker for Angiogenesis Inhibitors: The Motesanib Experience
por: Bass, Michael B., et al.
Publicado: (2014)

Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer
por: Liontos, Michalis, et al.
Publicado: (2014)

The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors
por: Rosen, Lee S, et al.
Publicado: (2013)

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients
por: Heestand, Gregory M., et al.
Publicado: (2017)

Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors
por: Caenepeel, Sean, et al.
Publicado: (2010)

Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study
por: Kotasek, Dusan, et al.
Publicado: (2011)

Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2012)

Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer
por: Burris, Howard, et al.
Publicado: (2011)

Correction: Challenges in Developing a Validated Biomarker for Angiogenesis Inhibitors: The Motesanib Experience
Publicado: (2015)

Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors
por: Benjamin, Robert S., et al.
Publicado: (2010)

The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada
por: Drucker, A., et al.
Publicado: (2008)

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
por: De Boer, Richard H., et al.
Publicado: (2012)

Ab-initio and Conformational Analysis of a Potent VEGFR-2 Inhibitor: A Case Study on Motesanib
por: Ebadi, Ahmad, et al.
Publicado: (2014)

Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate
por: Sawaki, Akira, et al.
Publicado: (2009)

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2018)

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial
por: Aranda, Enrique, et al.
Publicado: (2020)

A phase I study of ABT-510 plus bevacizumab in advanced solid tumors
por: Uronis, Hope E, et al.
Publicado: (2013)

Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib – Results of NCI/CTEP Protocol 9048
por: Semrad, Thomas J, et al.
Publicado: (2019)

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab
por: Falchook, Gerald S, et al.
Publicado: (2014)

Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non–small-cell lung cancer xenograft models
por: Coxon, Angela, et al.
Publicado: (2012)

A case report of motesanib-induced biliary sludge formation causing obstructive cholangitis with acute pancreatitis treated by endoscopic sphincterotomy
por: Song, Jay, et al.
Publicado: (2016)

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2
por: Bahleda, Rastislav, et al.
Publicado: (2018)

A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma
por: Peeters, M, et al.
Publicado: (2013)

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
por: Subbiah, Vivek, et al.
Publicado: (2020)

Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload
por: Kondrashov, Aleksei, et al.
Publicado: (2023)

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models
por: Oliva, P, et al.
Publicado: (2012)

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
por: Piha-Paul, Sarina A., et al.
Publicado: (2014)

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers
por: Sen, Shiraj, et al.
Publicado: (2018)

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
por: Gong, Hongyu, et al.
Publicado: (2023)

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
por: Dean, E, et al.
Publicado: (2012)

Actionability and precision oncology
por: Schwaederle, Maria, et al.
Publicado: (2015)

The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match
por: Subbiah, Vivek, et al.
Publicado: (2018)

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic
por: Agashe, Ruchi, et al.
Publicado: (2020)

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench
por: Subbiah, Vivek, et al.
Publicado: (2022)

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors
por: Falchook, Gerald S., et al.
Publicado: (2015)

Bevacizumab: Off-label use in ophthalmology
por: Grisanti, Salvatore, et al.
Publicado: (2007)

A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
por: Gorbunova, Vera, et al.
Publicado: (2018)

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial
por: Yamada, Y, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_t6ie77s3ndo64iqkfivtb3k95l